BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35773658)

  • 21. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
    Basse C; Régaldo-Saint Blancard L
    Bull Cancer; 2023 Sep; 110(9):869-871. PubMed ID: 37442707
    [No Abstract]   [Full Text] [Related]  

  • 22. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
    Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
    J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
    Miao K; Zhang X; Wang H; Si X; Zhang L
    Thorac Cancer; 2023 May; 14(13):1162-1170. PubMed ID: 36944506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Morise M; Kato T; Matsumoto S; Inoue T; Sakamoto T; Tokito T; Atagi S; Kozuki T; Takeoka H; Chikamori K; Shinagawa N; Tanaka H; Horii E; Adrian S; Bruns R; Johne A; Paik PK; Sakai H
    Cancer Sci; 2024 Apr; 115(4):1296-1305. PubMed ID: 38402853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
    Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
    Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW; Chang JW; Wu CE
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
    Deng HY; Qiu XM; Zhu DX; Tang XJ; Zhou Q
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4623-4628. PubMed ID: 36171456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Current Landscape for
    Desai A; Cuellar S
    J Adv Pract Oncol; 2022 Jul; 13(5):539-544. PubMed ID: 35910499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
    Xia Y; Jin R; Li M; Lan F; Zhu H; Yu Y; Miao D; Wang Q; Zhou Y; Selvaggi G; Ying S; Zhang J; Shen H; Le X; Li W
    Cancer Lett; 2023 May; 561():216140. PubMed ID: 36948240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
    Mazieres J; Paik PK; Garassino MC; Le X; Sakai H; Veillon R; Smit EF; Cortot AB; Raskin J; Viteri S; Wu YL; Yang JCH; Ahn MJ; Ma R; Zhao J; O'Brate A; Berghoff K; Bruns R; Otto G; Johne A; Felip E; Thomas M
    JAMA Oncol; 2023 Sep; 9(9):1260-1266. PubMed ID: 37270698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tepotinib in Non-Small-Cell Lung Cancer with
    Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
    N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
    Batteson R; Hook E; Wheat H; Hatswell AJ; Vioix H; McLean T; Alexopoulos ST; Baijal S; Paik PK
    Target Oncol; 2024 Mar; 19(2):191-201. PubMed ID: 38492157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
    Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
    Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Kato T; Yang JC; Ahn MJ; Sakai H; Morise M; Chen YM; Han JY; Yang JJ; Zhao J; Hsia TC; Berghoff K; Bruns R; Vioix H; Lang S; Johne A; Le X; Paik PK
    Br J Cancer; 2024 Jun; 130(10):1679-1686. PubMed ID: 38575731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of
    Yu Y; Zhang Q; Zhang J; Lu S
    J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
    Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
    Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
    Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.